# A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)

> **NCT01106352** · PHASE1,PHASE2 · COMPLETED · sponsor: **Bayer** · enrollment: 70 (actual)

## Conditions studied

- Bone Metastases
- Castration-Resistant Prostate Cancer

## Interventions

- **DRUG:** Radium-223 dichloride (Xofigo, BAY88-8223)
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT01106352
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07
- **Primary completion:** 2015-06
- **Final completion:** 2015-06
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2017-01-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01106352

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01106352, "A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01106352. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*